THROMBATE III delivers trusted therapy

Low risk of major bleeding complications, even in the presence of heparin1

  • The anticoagulant effect of heparin is enhanced by concurrent treatment with THROMBATE III in patients with HATD. Thus, in order to avoid bleeding, the dosage of heparin (or low molecular weight heparin) may need to be reduced during treatment with THROMBATE III

No known contraindications1

There has never been a confirmed case of virus transmission with THROMBATE III1

  • Because THROMBATE III is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product
Use THROMBATE III to replace what is normally present in the body

THROMBATE III is a human antithrombin concentrate indicated in patients with HATD for1:

  • Treatment and prevention of thromboembolism
  • Prevention of perioperative and peripartum thromboembolism

THROMBATE III is simple to use

Has one dosing formula1

  • Bolus intravenous infusion
  • Loading dose on day 1*
THROMBATE III antithrombin III [human] dosing and administration illustration

Provides for convenient storage and reconstitution1

  • No refrigeration required
    • Store at room temperature (not to exceed 25ºC, 77ºF)
    • No need to thaw
  • Single-use vial (500 IU potency)
  • Sterile water for injection (10 mL), transfer needle, and filter needle provided

Can be used before, during, and after surgery

Hypersensitivity reactions may occur. Should evidence of an acute hypersensitivity reaction be observed, promptly interrupt the infusion and begin appropriate treatment.

THROMBATE III can provide predictable amounts of AT at the point of care

IMPORTANT SAFETY INFORMATION


THROMBATE III® (antithrombin III [human]) is indicated in patients with hereditary antithrombin deficiency for treatment and prevention of thromboembolism and for prevention of perioperative and peripartum thromboembolism.

Hypersensitivity reactions may occur. Should evidence of an acute hypersensitivity reaction be observed, promptly interrupt the infusion and begin appropriate treatment.

Because THROMBATE III is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product.

Perform coagulation tests to avoid excessive or insufficient anticoagulation and monitor for bleeding or thrombosis. Measure functional plasma AT levels with amidolytic or clotting assays; do not use immunoassays.

In clinical studies, the most common adverse reactions (≥ 5% of subjects) were dizziness, chest discomfort, nausea, dysgeusia, and pain (cramps).

The anticoagulant effect of heparin is enhanced by concurrent treatment with THROMBATE III in patients with hereditary AT deficiency. Thus, in order to avoid bleeding, the dosage of heparin (or low molecular weight heparin) may need to be reduced during treatment with THROMBATE III.

Please see full Prescribing Information for THROMBATE III.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.

Reference: 1. THROMBATE III® (antithrombin III [human]) Prescribing Information. Grifols.